Product Description
Mechanisms of Action:
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Bulgaria | China | Germany | Hong Kong | India | Ireland | Poland | Slovenia | Taiwan | Tunisia
Approved Indications: None
Known Adverse Events: None
Company: Air Force Medical Center
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2500095376 |
ChiCTR2500095376 | N/A |
Not yet recruiting |
Diabetic Foot |
2026-12-31 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/15/2024 |
PubMed |
Formononetin alleviates cerebral ischemia-reperfusion injury in rats by targeting the PARP-1/PARG/Iduna signaling pathway. |
|
04/10/2024 |
PubMed |
Phosphatase-degradable nanoparticles providing sustained drug release. |
|
01/01/2024 |
PubMed |
Comparative Evaluation of Medicinal Plant Extracts and Antimicrobial Magistrals. |